The Trump administration’s proposed 0.09% increase in Medicare Advantage rates for 2027 falls well below analyst expectations of 4%–6%, creating pressure on CVS’s benefits arm, which accounts for more than one-third of company revenue. This modest boost is likely to intensify challenges from rising medical costs, as narrow single-digit margins in the Aetna unit may be further squeezed. Investors will be watching how CVS adjusts benefit designs and network strategies to offset the shortfall in rate growth and protect profitability in its insurance operations.

In the third quarter, BI Asset Management Fondsmaeglerselskab A S reduced its position in CVS by 30.1%, selling 166,058 shares and ending the period with 386,062 shares valued at approximately $27.5 million. Meanwhile, Savant Capital LLC increased its stake by 33.5%, adding 18,507 shares to reach 73,762 shares, and Envestnet Asset Management Inc. bought 51,076 shares, bringing its total to 1.99 million. Overall, nearly 81% of CVS shares remain held by institutions and hedge funds, underscoring the importance of fund flows in driving near-term stock performance.

Analyst projections for the quarter ended December 2025 indicate that CVS’s Pharmacy and Consumer Wellness segment could lead revenue gains, supported by prescription volume growth and expanded store-based clinical services. Industry models suggest same-store prescription fills may rise by low‐single digits, while the rollout of HealthHUB locations and MinuteClinic expansions is expected to contribute incremental revenue. Investors will key on segment margin trends and customer visit metrics to assess whether retail pharmacy can offset headwinds in the benefits business.